Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
54
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
09 May 2024 01:10
•
Issuer-paid
Oryzon Genomics - Doubling down on clinical activity in 2024
Oryzon’s Q124 results emphasised the company’s focus on advancing and expanding its CNS and oncology pipelines, driven by its core assets,...
Edison Investment Research
Follow
218 Views
Share
bullish
•
Oryzon Genomics
•
10 Apr 2024 01:10
•
Issuer-paid
Oryzon Genomics - FDA green light for SCLC combination trial
With the FDA investigational new drug (IND) application clearance, Oryzon can commence its Phase I/II cooperative research and development...
Edison Investment Research
Follow
300 Views
Share
bullish
•
Oryzon Genomics
•
05 Apr 2024 19:10
•
Issuer-paid
Oryzon Genomics - Third time is a charm; INNOVATIVE SME Seal
For the third consecutive time, Oryzon Genomics has received the INNOVATIVE SME Seal from the Spanish Ministry of Science and Innovation. This...
Edison Investment Research
Follow
406 Views
Share
bullish
•
Oryzon Genomics
•
06 Mar 2024 01:12
•
Issuer-paid
Oryzon Genomics - Approaching a period of inflection
ORY FY23 results announcement covered an eventful period for the company’s pipeline, capped by the release of top-line data from the Phase IIb...
Edison Investment Research
Follow
223 Views
Share
bullish
•
Oryzon Genomics
•
30 Jan 2024 07:11
•
Issuer-paid
Oryzon Genomics - KOL event: Offering a real-world solution in BPD
Oryzon hosted a key opinion leader (KOL) event highlighting the potential of vafidemstat in borderline personality disorder (BPD). The KOLs...
Edison Investment Research
Follow
160 Views
Share
Previous
1
2
3
4
5
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x